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Summary
Breast cancer recurrence is a fundamental clinical manifestation of tumor progression and represents the principal cause
of death from this disease. Using a conditional transgenic mouse model for the recurrence of HER2/neu-induced mam-
mary tumors, we demonstrate that the transcriptional repressor Snail is spontaneously upregulated in recurrent tumors
in vivo and that recurrence is accompanied by epithelial-to-mesenchymal transition (EMT). Consistent with a causal role
for Snail in these processes, we show that Snail is sufficient to induce EMT in primary tumor cells, that Snail is sufficient
to promote mammary tumor recurrence in vivo, and that high levels of Snail predict decreased relapse-free survival in
women with breast cancer. In aggregate, our observations strongly implicate Snail in the process of breast cancer recur-
rence.S I G N I F I C A N C E
Breast cancer is the most common malignancy diagnosed among women worldwide and is the leading cause of cancer mortality.
Among the more than 5 million women currently living with a diagnosis of breast cancer, recurrence represents the most common
cause of death from this disease. Nevertheless, while recurrence constitutes a problem of unrivaled clinical importance, little is
known about the mechanisms underlying it. Our findings demonstrate that Snail is sufficient to promote mammary tumor recurrence
in mice and that its expression is associated with rapid tumor recurrence in women independently of established prognostic factors.
These observations provide in vivo genetic evidence for a molecular pathway contributing to mammary tumor recurrence and
suggest that Snail may represent a target for cancer therapy.Introduction
Breast cancer is the most common malignancy diagnosed
among women worldwide and is the leading cause of cancer
mortality (Parkin et al., 2005). In 2005, more than 1.1 million
women will be diagnosed with breast cancer, and over 400,000
women will die from this disease. While breast cancer inci-
dence has steadily increased in Western countries, breast can-
cer mortality rates have declined for more than a decade such
that nearly 90% of women diagnosed with breast cancer sur-
vive for at least 5 years. As a consequence of its high incidence
and favorable prognosis, breast cancer is the most prevalent
cancer in the world today (Parkin et al., 2005). Among these
women, tumor dormancy followed by recurrence—local, re-
gional, or distant—represents the most common cause of
breast cancer mortality.
Although recurrence generally occurs relatively early, be-
tween 1 and 2 years after surgery (Demicheli et al., 2004;
Saphner et al., 1996), a considerable proportion of breast can-
cers that appear cured resurface as local or distant tumor re-
currences 10 or 20 years after surgery (Fisher et al., 2004;CANCER CELL : SEPTEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEWeiss et al., 2003). This suggests that in many cases tumor
cells have already disseminated to distant sites by the time that
breast cancers are diagnosed. Indeed, analysis of bone mar-
row specimens indicates that residual cancer cells are detecta-
ble in up to 40% of primary breast cancer patients who lack
clinical or histopathological signs of metastasis (Pantel et al.,
2003). These and other observations argue that breast cancer
recurrence represents a major obstacle to curing this disease.
Despite the central role of recurrence in breast cancer mor-
tality, little is known about the cellular or molecular events re-
sponsible. A limited number of clinical and molecular charac-
teristics of breast cancers have been shown to correlate with
relapse-free survival. In women with breast cancer, the most
important factors for predicting recurrence are tumor size and
the extent of lymph node involvement (Carter et al., 1989; Vala-
gussa et al., 1978). In addition, a number of molecular markers
for aggressive tumor behavior can be used to identify breast
cancer patients at high risk for recurrence, including HER2/neu
expression, c-myc amplification, and estrogen receptor (ER)
negativity (Esteva and Hortobagyi, 2004; Schlotter et al., 2003).
However, neither these nor other molecular prognostic markersR INC. DOI 10.1016/j.ccr.2005.07.009 197
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rence. As such, their mechanistic relationship to this process
remains speculative.
Elucidating the molecular mechanisms that allow tumors to
evade primary therapy and recur is a critical goal of breast can-
cer research. In particular, understanding the biology of tumor
latency and recurrence would permit improvements in the pre-
diction, prevention, and treatment of breast cancer recurrence.
Achieving this goal, however, has been hampered by the lack
of animal models that faithfully recapitulate this fundamental
step in breast cancer progression. Such models are essential
for the rational development and testing of therapeutics tar-
geted against the residual population of neoplastic cells re-
sponsible for the majority of breast cancer deaths.
Further compounding difficulties in understanding recur-
rence is the limited availability of clinical material for analysis.
While molecular profiles for primary human breast cancers
have become widely available, no comprehensive molecular
analysis of recurrent human breast cancers currently exists.
Consequently, not only do we lack information on pathways
causally involved in recurrence, but we also lack a basic under-
standing of the specific molecular features that distinguish re-
current breast cancers from the primary tumors from which
they arose.
One molecular prognostic marker for poor clinical outcome
in breast cancer patients is the proto-oncogene HER2/neu.
Amplification and overexpression of this receptor tyrosine ki-
nase occurs in 15%–30% of primary human breast cancers
and is associated with aggressive tumor behavior, high rates
of relapse, and poor prognosis (Berger et al., 1988; Slamon et
al., 1987). In recent years trastuzumab (Herceptin), a neutraliz-
ing antibody that inhibits the activity of HER2/neu, has been
tested in clinical trials for patients with HER2/neu-amplified
breast cancers. The efficacy of this agent in slowing disease
progression and prolonging survival, even in advanced stages
of disease, has been demonstrated in multiple studies (Baselga
et al., 1996; Slamon et al., 2001; Vogel et al., 2002; Wang et
al., 2001). However, even in cases in which trastuzumab is
combined with standard chemotherapeutic regimens, breast
cancers typically become resistant to therapy and recur (Horto-
bagyi, 2001). As with cancer recurrence in general, the mecha-
nisms by which HER2/neu-amplified breast tumor cells evade
the blockade of this pathway are poorly understood.
Given the importance of the proto-oncogene HER2/neu in
human breast cancers, we have used a mammary-specific,
conditional transgenic model to investigate the effects of neu
pathway downregulation on the regression and recurrence of
mammary tumors induced by this oncogene. Specifically, we
have used the tetracycline-regulatory system to inducibly ex-
press an activated form of neu in the mammary epithelium of
transgenic mice (Moody et al., 2002). When treated with doxy-
cycline, these mice develop multiple invasive mammary adeno-
carcinomas that regress to a nonpalpable state upon targeted
downregulation of the neu pathway. However, consistent with
the behavior of human malignancies, the vast majority of mice
harboring fully regressed tumors ultimately develop recur-
rences in the absence of doxycycline treatment and neu ex-
pression. As such, this model recapitulates key features of the
natural history of human breast cancers relevant to tumor re-
currence.
We have employed this conditional transgenic mouse model198to investigate secondary pathways involved in breast cancer
progression and escape. We now report the identification of a
molecular pathway involved in spontaneous mammary cancer
recurrence. We show that recurrent neu-induced mammary tu-
mors display phenotypic and molecular alterations characteris-
tic of the epithelial-to-mesenchymal transition (EMT) and spon-
taneously upregulate expression of Snail, a transcriptional
repressor previously implicated in EMT. We further show that
Snail is sufficient both to induce EMT in neu-induced primary
tumor cells and to promote rapid tumor recurrence in vivo fol-
lowing downregulation of the neu pathway.
Finally, analysis of four independent microarray expression
data sets derived from prospectively harvested human breast
cancer samples revealed that high levels of Snail expression
strongly predict decreased relapse-free survival in women with
breast cancer independently of most currently used prognostic
indicators for breast cancer. These studies identify a molecular
pathway involved in mammary tumor recurrence in vivo and
suggest that Snail may play a role in the progression of human
breast cancers.
Results
Fully regressed neu-induced tumors recur spontaneously
following a period of dormancy
We previously generated a doxycycline-inducible bitransgenic
mouse model for HER2/neu-induced mammary carcinogene-
sis, referred to as MMTV-rtTA/TetO-NeuNT (MTB/TAN) (Moody
et al., 2002). When expression of this activated form of neu
is induced with doxycycline, MTB/TAN mice develop multiple
invasive mammary adenocarcinomas, many of which metasta-
size to the lung (Moody et al., 2002). Downregulation of neu
expression in the vast majority of these fully formed mammary
tumors results in their regression to a nonpalpable state. How-
ever, following a latent period, some mice bearing fully re-
gressed tumors develop spontaneous tumor recurrences in the
absence of neu expression.
To investigate the mechanisms responsible for the recur-
rence of neu-induced mammary tumors, we first generated a
large cohort of tumor-bearing mice. Of 507 neu-induced pri-
mary mammary tumors monitored in 62 MTB/TAN mice, 493
(97%) regressed to a nonpalpable state following doxycycline
withdrawal and downregulation of the neu pathway. Following
doxycycline withdrawal, two neu-induced primary tumors failed
to regress, whereas an additional 11 primary tumors regressed
partially and then rapidly resumed neu-independent growth.
Thus, in nearly all cases the vast majority of cells within neu-
induced primary tumors remain dependent upon neu for main-
tenance of the transformed state.
Fifty mice in which all tumors had regressed to a nonpalpa-
ble state following doxycycline withdrawal were monitored for
extended periods of time in the absence of doxycycline. Over
a 1 year period, 43 (86%) of these mice spontaneously devel-
oped recurrent tumors with a mean latency of 117 days (Figure
1A). Formally, doxycycline-independent tumors arising in mice
that had previously harbored mammary tumors could represent
either genuine recurrences of neu-initiated tumors or the de novo
formation of tumors in the absence of doxycycline. Our re-
peated observations that uninduced MTB/TAN animals do not
develop tumors, even over periods exceeding 18 months, and
that recurrent tumors always appear at a site at which a pri-CANCER CELL : SEPTEMBER 2005
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cur spontaneously following a latent period
A: Recurrence-free survival for never-induced
MTB/TAN mice (n = 13) and MTB/TAN mice dein-
duced after developing primary tumors on dox-
ycycline (n = 62) (SD 48, range 27–222).
B: Timing of tumor regression and recurrence for
individual neu-induced tumors. The time of dox-
ycycline withdrawal (day 0) from tumor-bearing
mice is indicated by an arrow. A bracket indi-
cates the range of times (relative to doxycy-
cline withdrawal) at which neu was initially in-
duced by doxycycline treatment.
C: Luciferase imaging of tumor-bearing MTB/
TAN mice demonstrating that recurrent tumors
do not express the TAN transgene in the ab-
sence of doxycycline. A mouse with multiple pri-
mary tumors (arrows) on doxycycline is shown
with (B) and without (A) luciferase activity over-
lay. The same mouse after full regression of tu-
mors off doxycycline is shown with luciferase ac-
tivity overlay (C). A second mouse with a
recurrent tumor in mammary gland 3R (arrow)
lacking luciferase activity is shown in D.mary tumor had previously existed, suggest that these doxycy-
cline-independent tumors represent bona fide recurrences.
To confirm that doxycycline-independent recurrent tumors
arise from cells within the original primary tumor, we implanted
small fragments of primary tumors from MTB/TAN mice onto
the flanks of wild-type mice. Grafted hosts were initially main-
tained on doxycycline to permit tumor outgrowth, after which
time doxycycline was withdrawn. Similar to the behavior of
primary mammary tumors in MTB/TAN mice, grafted tumors
regressed to a nonpalpable state following doxycycline with-
drawal, and a subset of these regressed tumor grafts eventu-
ally recurred at the original site following a latent period. Since
tumors in nontransgenic hosts could only arise from grafted
cells, these data confirm that doxycycline-independent tumors
that arise in MTB/TAN mice harboring fully regressed tumors
are in fact recurrences derived from cells within the primary
tumor. This conclusion is further strengthened by our subse-
quent demonstration that epithelial cell cultures derived from
primary neu-induced mammary tumors also give rise to recur-
rences when subjected to a similar grafting protocol (see
below).CANCER CELL : SEPTEMBER 2005Analysis of mammary tumor behavior in intact MTB/TAN
mice revealed that recurrent tumors arose stochastically over
an 8 month period, frequently following a prolonged latency
period (Figure 1B). The concept of tumor latency in breast can-
cer patients arises in part from the inability of continuous
growth models to explain the kinetics of tumor recurrence in
patients, as well as the lack of a relationship between the
length of time from surgery to tumor recurrence and the growth
rate of tumors once they reappear. Analogous to the situation
in humans, the latency for tumor recurrence in MTB/TAN mice
was considerably longer than that observed for primary tumor
development following neu induction (mean latency, 117 ver-
sus 42 days, respectively; Figure 1A and Moody et al., 2002).
Similarly, the growth rate of recurrent tumors once they reap-
peared was unrelated to the length of time between tumor re-
gression and tumor recurrence (Figure 1B). Thus, as with breast
cancer patients, the timing of tumor recurrence and the kinetics
of recurrent tumor growth cannot be explained by a model
postulating constant growth of residual tumor cells. In aggre-
gate, our observations strongly suggest that deinduced MTB/
TAN mice harbor residual neoplastic cells at the sites of their199
A R T I C L Eoriginal tumors that persist in a latent state for variable periods
of time before reemerging as recurrent disease.
Fully regressed neu-induced tumors recur
in the absence of neu expression
In theory, doxycycline-independent tumor recurrences could
result from doxycycline-independent activation of the NeuNT
transgene, compensatory upregulation of endogenous ErbB2,
or activation of neu-independent growth and/or survival path-
ways. Since the TetO-NeuNT transgene contains a bicistronic
IRES-firefly luciferase cassette, transgene expression can be
monitored longitudinally in mice by noninvasive in vivo imaging
of luciferase. As predicted, luciferase activity was readily visu-
alized within primary tumors in MTB/TAN mice maintained on
doxycycline, whereas mice maintained off doxycycline harbor-
ing either fully regressed or recurrent tumors did not express
detectable luciferase activity (Figure 1C). In addition, Northern
analysis as well as anti-ErbB2 immunohistochemistry failed to
detect upregulation of endogenous ErbB2 in recurrent tumors
(Figure 2C and data not shown). These observations indicate
that spontaneous recurrence of neu-induced mammary tumors
occurs by a process other than the doxycycline-independent
reactivation of the NeuNT transgene or compensatory upregu-
lation of endogenous ErbB2.
Taken together, these results suggest that a subset of cells
in neu-induced primary tumors are able to progress to a state
that is independent of neu overexpression for survival and
growth. Moreover, the fact that MTB/TAN mice bearing fully
regressed tumors typically relapse following a latency of up to
8 months indicates that these mice harbor viable residual neo-
plastic cells that persist in the mammary gland for extended
periods of time.
Recurrent tumors display characteristics of EMT
Neu-induced mammary adenocarcinomas in MTB/TAN mice
maintained on doxycycline display a characteristic epithelial
morphology and stain positively for the luminal epithelial
marker cytokeratin 8 (CK8) (Moody et al., 2002). Since mam-
mary tumors induced in mice by different oncogenic pathways
have been shown to exhibit distinct histopathological “signa-
tures,” we reasoned that doxycycline-independent tumor re-
currences that no longer expressed neu might not exhibit the
classic neu phenotype (Cardiff et al., 1991). In agreement with
this prediction, histopathological examination of multiple neu-
negative, doxycycline-independent recurrent tumors revealed
that the vast majority of these tumors were composed of spin-
dle-shaped cells with mesenchymal morphology (Figure 2A).
Furthermore, immunohistochemical analysis demonstrated
that recurrent tumors had downregulated CK8, although occa-
sional CK8-positive cells were detected (Figure 2A).
These findings led us to hypothesize that neu-induced mam-
mary tumors undergo EMT prior to their reemergence as neu-
independent recurrent tumors. Consistent with this hypothesis,
Northern analysis confirmed the absence of NeuNT transgene
expression in recurrent tumors and further revealed that ex-
pression of the mesenchymal markers vimentin and fibronectin
were upregulated (Figure 2C). Conversely, a striking reduction
in expression of the epithelial marker E-cadherin was observed
in virtually every neu-independent recurrent tumor (Figure 2C).
E-cadherin is an essential component of adherens junctions in
epithelial cells, and its expression is commonly lost in EMT.200Immunofluorescence studies confirmed that recurrent tumors
downregulate expression of CK8 and E-cadherin and upregu-
late expression of the mesenchymal marker S100A4 (fibro-
blast-specific protein [Fsp1]) (Figure 2D). These findings de-
monstrate that recurrent tumors display multiple features
characteristic of cells that have undergone EMT.
Mesenchymal recurrences arise from primary
epithelial tumors
Since primary neu-dependent mammary tumors and doxycy-
cline-independent tumor recurrences exhibit strikingly different
morphological phenotypes, we wished to confirm that mes-
enchymal recurrences arise from primary epithelial tumors. Two
lines of evidence indicate that this is indeed the case. First, we
performed both Northern and histological analysis on the small
number of neu-induced primary mammary tumors that re-
gressed only partially following doxycycline withdrawal before
resuming growth. This analysis revealed that incompletely re-
gressing doxycycline-independent primary tumors, which remain
clinically apparent throughout their period of partial regression
and regrowth, display the same spindle cell phenotype and
identical molecular characteristics with respect to markers of
EMT as doxycycline-independent recurrences (Figure 2C and
data not shown). This suggests that the same cellular pro-
cesses that lead to tumor recurrence also contribute to the de-
velopment of neu-independent primary tumors.
Second, primary MTB/TAN tumors grafted onto the flanks of
wild-type mice were allowed to engraft and grow on doxycy-
cline before being induced to regress to a nonpalpable state
by withdrawal of doxycycline treatment. Grafted mice bearing
fully regressed tumors were monitored for spontaneous recur-
rence in the absence of doxycycline. Primary tumor grafts were
biopsied prior to doxycycline withdrawal, and doxycycline-
independent tumors that eventually recurred at graft sites were
harvested. Histological analysis of these matched sets of pri-
mary and recurrent tumor grafts demonstrated that primary tu-
mor grafts displayed the classic neu epithelial phenotype,
whereas doxycycline-independent recurrences that arose at
the same sites had acquired a mesenchymal phenotype (Figure
2B). Taken together, these two lines of evidence indicate that
mesenchymal-appearing, doxycycline-independent tumors that
arise at the site of fully regressed neu-induced neoplasms consti-
tute recurrences of epithelial tumors that have undergone EMT.
Snail, an inducer of EMT, is spontaneously upregulated
in recurrent mammary tumors
A major regulator of EMT during embryonic mesoderm and
neural crest development is the zinc finger transcription factor
Snail. First identified in Drosophila mutant embryos exhibiting
defective mesoderm invagination, Snail is required for normal
mesoderm development in mice (Grau et al., 1984; Carver et
al., 2001). In addition, Snail directly represses E-cadherin tran-
scription in both mouse and human epithelial cell lines (Batlle
et al., 2000; Cano et al., 2000). Similarly, both Snail and its
closely related family member Slug can repress endogenous
E-cadherin expression in human breast cancer cell lines (Hajra
et al., 2002). Consistent with this, invasive ductal carcinomas
of the breast have been reported to express Snail in a manner
that is inversely correlated with E-cadherin expression (Cheng
et al., 2001).
In light of the association of Snail with EMT, we wished toCANCER CELL : SEPTEMBER 2005
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tics of epithelial-to-mesenchymal transition
A: H&E- and anti-CK8-stained sections from re-
presentative MTB/TAN primary (neu-expressing)
and MTB/TAN recurrent (neu-negative) tumors
demonstrating the transition from epithelial to
mesenchymal morphology and marker expres-
sion. Magnification, 400×.
B: H&E-stained sections of two primary tumor
grafts allowed to engraft on doxycycline and
biopsied while on doxycycline. Tumors either
partially regressed and then resumed growth in
the absence of doxycycline (T1) or completely
regressed and recurred at the same site (T2).
Magnification, 400×.
C: Northern analysis of primary and recurrent
MTB/TAN tumors for expression of epithelial and
mesenchymal markers. rRNA (18S) is shown as a
loading control.
D: Immunofluorescence (IF) analysis of CK8,
E-cadherin, and S100A4 expression in represen-
tative primary and recurrent tumors. Magnifica-
tion, 400×.determine whether Snail was upregulated in recurrent, neu-
induced mammary tumors that exhibited features of EMT.
Microarray analysis of doxycycline-independent MTB/TAN tu-
mors demonstrated a 9-fold increase in Snail expression com-
pared to primary MTB/TAN tumors (p = 8 × 10−6), whereas only
a 1.8-fold change in expression was detected in its closely re-
lated family member, Slug (p = 10−4) (Figure 3A). Northern
analysis confirmed that recurrent tumors express increased
levels of Snail compared to primary tumors (Figure 3B). Simi-
larly, consistent with their spindle cell appearance, primary
mammary tumors that regressed only partially prior to resum-
ing growth in a neu- and doxycycline-independent manner also
displayed increased levels of Snail (Figure 3B).
Snail induces EMT in primary neu-induced
tumor cells in vitro
Since we had observed a correlation between Snail expression
and acquisition of a mesenchymal phenotype in doxycycline-CANCER CELL : SEPTEMBER 2005independent tumors, we wished to test whether Snail could
induce EMT in primary neu-induced mammary tumor cells. Al-
though several studies in epithelial cell lines have demon-
strated that Snail expression can induce EMT, some normal
and malignant epithelial cell lines have proven to be resistant
to this phenomenon in vitro (Batlle et al., 2000; Cano et al.,
2000; Zhou et al., 2004). To determine whether Snail is capable
of inducing EMT in neu-expressing tumor cells, we transduced
primary tumor cells maintained on doxycycline with a retroviral
vector encoding Snail or with the control retroviral vector pk1.
Infected cells were selected in puromycin-containing media,
and immunoblotting was performed to assess Snail expression
in transduced cells (Figure 3C). Within two weeks of transduc-
tion, pk1-Snail-infected cells acquired a fibroblastic spindle cell
phenotype accompanied by loss of cell-to-cell contacts (Figure
3D). In contrast, pk1-infected control cells retained their epithe-
lial morphology. These results demonstrate that Snail expres-201
A R T I C L EFigure 3. Snail is spontaneously upregulated in
recurrent mammary tumors and induces EMT in
primary neu-induced tumor cells
A: Microarray analysis of mean Snail and Slug
expression levels in primary and recurrent tu-
mors. Expression levels were significantly dif-
ferent between primary tumors and recurrent
tumors for both genes (p = 8 × 10−6 for Snail; p =
0.0001 for Slug). Error bars indicate standard er-
ror of the mean.
B: Northern analysis of Snail expression in pri-
mary, recurrent, and incompletely regressing
(Inc. Reg.) tumors. rRNA (28S) is shown as a load-
ing control.
C: Western analysis of Snail expression in pk1-
and pk1-Snail-infected primary tumor cells.
D: Photomicrographs of pk1- and pk1-Snail-
infected primary tumor cells showing spindle
cell morphology of Snail-expressing cells.
E: IF analysis of uninfected primary tumor cells,
uninfected recurrent tumor cells, and primary
tumor cells infected with pk1 or pk1-Snail. Mag-
nification, 400× (D and E).sion in neu-induced primary tumor cells is sufficient to induce
the acquisition of a spindle-shaped morphology.
Since the transition to a spindle-shaped morphology is con-
sistent with EMT, we next asked whether alterations associated
with EMT also occurred at the molecular level. Primary tumor
cells transduced with pk1- or pk1-Snail-expressing retroviral
vectors, as well as nontransduced primary and recurrent tumor
cells, were immunostained with antibodies directed against
epithelial and mesenchymal markers. As expected, CK8 and
E-cadherin were expressed in both uninfected and pk1-infected
primary tumor cells, whereas expression of these epithelial
markers was lost in cells cultured from recurrent tumors (Figure
3E). Conversely, the mesenchymal markers S100A4 and fibro-
nectin were highly upregulated in the recurrent tumor cell line
compared to uninfected or pk1-infected primary tumor cells.
Notably, while complete repression of E-cadherin expression202was observed in primary tumor cells transduced with pk1-Snail,
CK8 expression was lost in only a fraction of Snail-expressing
primary tumor cells (Figure 3E). Similarly, a marked increase in
S100A4 and fibronectin expression was evident in a subset of
pk1-Snail-infected primary tumor cells. The upregulation of
mesenchymal markers in only a subset of Snail-transduced
cells contrasts with the ubiquitous upregulation of mesenchy-
mal markers in recurrent tumor cells. This differential behavior
may be due to the concurrent expression of neu in tumor cell
lines maintained on doxycycline, since neu may impede Snail’s
ability to induce the full phenotypic manifestations of EMT. Al-
ternately, full manifestation of the EMT phenotype may require
additional genetic or epigenetic alterations besides Snail ex-
pression. Nonetheless, complete transition to a mesenchymal
morphology occurs in pk1-Snail-infected cells. In aggregate,
these observations demonstrate that Snail expression triggersCANCER CELL : SEPTEMBER 2005
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mary tumor cells.
Snail promotes the recurrence of neu-induced
primary tumors
Since virtually all transgene-independent MTB/TAN recurrent
tumors display a mesenchymal phenotype and express high
levels of Snail, we hypothesized that Snail may directly pro-
mote tumor recurrence. To investigate this possibility, we
grafted pk1-Snail- or pk1-transduced primary tumor cells onto
the flanks of nude mice maintained on doxycycline. Both sets
of cells formed tumors with equal efficiency. As predicted, tu-
mor grafts derived from pk1-transduced primary tumor cells
displayed an epithelial morphology, whereas tumor grafts aris-
ing from pk1-Snail-transduced cells exhibited a mesenchymal
morphology despite continued expression of the neu onco-
gene (Figure 4A). To confirm that tumors derived from pk1-
Snail-transduced cells do not have altered NeuNT transgene
expression prior to the withdrawal of doxycycline, we assayed
luciferase activity levels in pk1- and pk1-Snail-transduced tu-
mor grafts harvested from mice maintained on doxycycline. As
expected, in mice maintained on doxycycline both pk1-Snail
and pk1 tumor grafts expressed high, comparable levels of the
NeuNT-IRES-Luciferase transgene (Figure 4B).
When pk1- and pk1-Snail-transduced tumor grafts reached
a size of 27 mm3, doxycycline was withdrawn. All tumors re-
gressed to a nonpalpable state following doxycycline with-
drawal regardless of Snail expression status. Strikingly, within
60 days of neu downregulation, 17 of 20 (85%) pk1-Snail-
transduced tumors recurred, whereas only 1 of 20 (5%) pk1-
transduced tumors recurred (p < 0.0001) (Figure 4C). Moreover,
similar to recurrent tumors that arose in tumor-bearing MTB/
TAN mice withdrawn from doxycycline, regressed pk1-Snail tu-
mor grafts that recurred in the absence of doxycycline lacked
detectable NeuNT transgene expression (Figure 4B).
Notably, pk1-Snail-induced recurrent tumors displayed a fi-
broblastic phenotype similar both to doxycycline-independent
tumor recurrences arising in MTB/TAN mice and to pk1-Snail-
transduced primary tumor grafts arising in mice maintained on
doxycycline (Figure 4A). Consistent with this, immunofluores-
cence analysis revealed the downregulation of E-cadherin
expression and upregulation of S100A4 in both doxycycline-
dependent pk1-Snail primary tumor grafts and doxycycline-
independent pk1-Snail recurrent tumor grafts (Figure 4D). In
contrast, high levels of E-cadherin and low levels of S100A4
were observed in epithelial-appearing pk1 control tumor grafts
growing in doxycycline-treated mice. Thus, Snail-induced re-
current tumors are morphologically and molecularly similar to
MTB/TAN recurrent tumors that arise in intact mice in the ab-
sence of NeuNT transgene expression. In aggregate, these
data demonstrate that Snail promotes the rapid recurrence of
primary tumor cells in vivo following downregulation of the
neu pathway.
Snail expression predicts decreased relapse-free survival
in women with breast cancer
Our observation that enforced Snail expression in primary tu-
mor cells promotes mammary tumor recurrence in mice raised
the question of whether Snail might play a similar role in the
recurrence of breast cancers in humans. If this were the case,
we reasoned that women with primary breast cancers express-CANCER CELL : SEPTEMBER 2005Figure 4. Snail promotes the recurrence of neu-induced primary tumors
A: H&E-stained sections from tumors formed by pk1- and pk1-Snail-infected
tumor cells harvested from mice on doxycycline, and from doxycycline-
independent, pk1-Snail-transduced recurrent tumors. Magnification, 400×.
B: Luciferase activity levels in pk1 and pk1-Snail tumors in mice on doxycy-
cline, and in pk1-Snail recurrent tumors (Rec) arising after doxycycline with-
drawal. n = 6 for each tumor type. Error bars indicate standard error of
the mean.
C: Recurrence-free survival for mice engrafted with pk1-infected and pk1-
Snail-infected primary tumor cells. Mice were removed from doxycycline
on day 0 after the injected tumor cells had formed a tumor w27 mm3 in
size. Recurrence rates were significantly higher in pk1-Snail-infected cells
(p < 0.0001).
D: IF analysis of tumors formed by pk1- and pk1-Snail-infected tumor cells
harvested from mice on doxycycline, and of doxycycline-independent,
pk1-Snail-transduced recurrent tumors. Magnification, 400×.ing high levels of Snail might relapse at a faster rate than
women whose breast cancers expressed lower levels of Snail.
Therefore, we examined four microarray expression data sets
derived from the analysis of primary human breast cancers in
which both Snail expression levels and clinical outcome were
reported. For each data set, tumor samples were classified as
either high or low Snail expressers based on array hybridization
levels (for two-color arrays) or absolute expression analysis p
values (for Affymetrix arrays). The relationship between Snail
expression level and 5 year relapse-free survival was then de-
termined.
In the first series of samples examined, Sorlie et al. profiled203
A R T I C L E74 locally advanced ER-positive and ER-negative primary
breast cancers from patients without distant metastases at the
time of presentation (Sorlie et al., 2003). Microarrays containing
probe sets capable of detecting Snail had been used in analyz-
ing 22 of these 74 samples. Applying the Kaplan-Meier estima-
tor to high and low Snail-expressing groups revealed a signifi-
cant correlation between breast cancers expressing high levels
of Snail and decreased relapse-free survival (p = 0.009) (Fig-
ure 5A).
A similar analysis of relapse-free survival was performed
using microarray data derived from 97 ER-positive and ER-
negative breast cancers that were lymph node-negative at pre-
sentation (van’t Veer et al., 2002). Similar to locally advanced
tumors, high Snail expression in node-negative human primary
breast cancers was significantly associated with decreased
distant relapse-free survival (p = 0.021) (Figure 5B). A third
analysis of the relationship between Snail expression and the
rate of distant relapse in 286 patients with lymph node-nega-
tive breast cancers (Wang et al., 2005) showed a similar signifi-
cant association (p = 0.029) between breast cancers express-
ing high levels of Snail and decreased relapse-free survival
(Figure 5C). Finally, we analyzed a fourth set of 60 hormoneFigure 5. Snail expression predicts decreased relapse-free survival in
women with breast cancer
Five year relapse-free survival for human tumors with low versus high Snail
expression in microarray data sets representing the following. A: Locally
advanced human breast cancers (Sorlie et al., 2003); B: lymph node-nega-
tive human breast cancers (van’t Veer et al., 2002); C: lymph node-nega-
tive, ER-positive, and ER-negative human breast cancers (Wang et al.,
2005); and D: hormone receptor-positive human breast cancers (Ma et
al., 2004).204receptor-positive breast cancers from patients without distant
metastases at the time of tumor resection (Ma et al., 2004).
Once again, a trend between high Snail expression and rapid
tumor recurrence was observed within this patient group, al-
though the association did not reach statistical significance
(p = 0.085) (Figure 5D).
Taken together, these data demonstrate that high levels of
Snail expression in human primary breast cancers consistently
predict decreased relapse-free survival. The demonstration that
four different Snail probes on four different microarray platforms
applied to four different patient sample sets representing 464
patients each yield the same result strongly suggests that the
association between Snail expression and relapse-free survival
is not specific to the particular probes used to detect Snail,
the particular platforms on which the microarray studies were
performed, or the particular characteristics of the patient pop-
ulations that were represented in these studies. Moreover,
since a significant association between Snail expression and
rate of relapse was observed for both locally advanced and
node-negative breast cancers, as well as among ER+ and ER−
breast cancers, this analysis suggests that Snail expression
may be an important prognostic indicator for breast cancer in
a variety of clinical contexts.
The prognostic significance of Snail expression
is comparable to classic prognostic indices
Having determined that Snail expression levels predict relapse-
free survival in women with breast cancer, we wished to com-
pare the magnitude of this association with currently used clin-
ical prognostic markers. Accordingly, the Cox proportional
hazards regression was used to calculate hazard ratios (HR) for
relapse based on Snail expression, tumor size, tumor grade,
lymph node status, ER status, and HER2 status (Table 1). This
analysis revealed that the risk of breast cancer relapse associ-
ated with high levels of Snail expression (HR >2-fold) is compa-
rable to those associated with currently used clinical prognos-
tic indicators, including that of ER status, tumor grade, and
lymph node status.
Snail predicts relapse-free survival independently
of other prognostic markers
Since several prognostic markers have previously been estab-
lished for human breast cancer, we asked whether the prog-
nostic significance of Snail was attributable to its correlation
with other markers of aggressive tumor behavior. Two charac-
teristics of breast cancers in women that have been found to
be strong predictors of relapse-free survival are tumor size at
diagnosis and lymph node status (Carter et al., 1989; Vala-
gussa et al., 1978). Therefore, we analyzed the association be-
tween Snail expression and tumor size by four methods: con-
tingency table analysis of binned Snail expression levels versus
binned tumor size; Snail expression level as a continuous vari-
able versus binned tumor size; binned Snail expression versus
tumor size as a continuous variable; and the correlation be-
tween Snail expression and tumor size, in which each is ana-
lyzed as a continuous variable. None of these methods re-
vealed a significant correlation between Snail expression and
tumor size in any of the three human breast cancer data sets
analyzed (Table 2).
Similarly, we attempted to correlate Snail expression with
lymph node status using both contingency table analysis andCANCER CELL : SEPTEMBER 2005
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Snail status Tumor size Tumor grade LN status ER status HER2 status
Sorlie HR ** 1.11 2.02* 1.13 2.59* 3.04*
95% CI ** 0.49–0.51 1.13–3.59 0.59–3.03 1.16–5.79 1.04–8.86
p value ** 0.810 0.017 0.494 0.021 0.042
van’t Veer HR 2.24* 1.73* 3.01* N/A 2.32* 4.10*
95% CI 1.11–4.53 1.19–2.53 1.60–5.68 N/A 1.28–4.19 1.72–9.80
p value 0.025 0.004 0.001 N/A 0.005 0.002
Wang HR 2.04* N/A N/A N/A 1.18 1.06
95% CI 1.06–3.92 N/A N/A N/A 0.76–1.85 0.63–1.80
p value 0.034 N/A N/A N/A 0.460 0.820
Ma HR 2.21 1.33 2.01 0.97 N/A 1.90
95% CI 0.87–5.57 0.80–2.23 0.94–4.30 0.44–2.14 N/A 0.45–8.13
p value 0.094 0.269 0.073 0.947 N/A 0.385
Hazard ratios, 95% confidence intervals, and p values for breast cancer relapse within 5 years of surgery, based on Snail expression grouping or previously described
prognostic factors. Data are presented for each of the four human breast cancer data sets analyzed. HR, hazard ratio; CI, confidence interval; LN, lymph node.
Statistically significant hazard ratios (p < 0.05) are indicated by asterisks. The hazard ratio is mathematically infinite, since no tumors with low Snail expression recurred.
No confidence interval or p value can be generated.relation between Snail expression and histological tumor grade
Table 2. p values for association between Snail expression and 5 year relapse-free survival or prognostic indicators
Analysis Sorlie van’t Veer Wang Ma
Relapse-free survival Log-rank test based on Snail status 0.009* 0.021* 0.029* 0.085
Tumor size Snail status versus size status 0.193 0.793 N/A 0.367
Snail expression versus size status 0.397 0.686 N/A 0.533
Snail status versus size 0.335 0.908 N/A 0.986
Snail expression versus size 0.456 0.737 N/A 0.522
Tumor grade Snail status versus grade status 0.104 0.454 N/A 0.644
Snail expression versus grade status 0.010* 0.965 N/A 0.287
Lymph node status Snail status and lymph node status 0.648 N/A N/A 1.000
Snail expression versus lymph node status 0.375 N/A N/A 0.162
ER status Snail status versus ER status 1.000 0.636 <0.0001* N/A
Snail expression versus ER status 0.601 0.901 0.0002* N/A
Snail status versus ESR1 expression 0.438 0.518 <0.0001* 0.024*
Snail expression versus ESR1 expression 0.146 0.806 <0.0001* 0.001*
Snail expression versus ESR1 expression in ER+ tumors 0.166 0.258 0.0621 <0.001*
Snail expression versus ESR1 expression in ER− tumors 0.784 0.475 0.0584 N/A
HER2 status Snail status versus HER2 status 1.000 0.660 0.7482 0.272
Snail expression versus HER2 status 0.505 0.455 0.3850 0.095
Snail status versus HER2 expression 0.217 0.843 0.0353* 0.707
Snail expression versus HER2 expression 0.373 0.933 0.1387 0.467
Ductal versus lobular Snail status versus histological status 1.000 N/A N/A 1.000
Snail expression versus histological status 0.293 N/A N/A 0.994
Sorlie subtype Snail status versus Sorlie subtype status 1.000 0.520 N/A N/A
classification Snail expression versus Sorlie subtype status 0.334 0.976 N/A N/A
Correlation between Snail expression and 5 year relapse-free survival, and between Snail expression and previously described prognostic factors for breast cancer. p
values are shown for each of the four human breast cancer data sets analyzed. “Status” designation refers to groupings of samples as described in the Experimental
Procedures. All other designations refer to the variable as continuous, based either on microarray-determined expression levels or on size. Contingency table analyses
(group versus group) were tested by Fisher’s exact test. Group versus continuous variable analyses were tested by ANOVA. Correlations between two continuous
variables were tested by the p value of the Pearson correlation coefficient. Asterisks indicate statistically significant correlations (p < 0.05).
2003). Of these, the basal and ERBB2+ subtypes have beenSnail expression level as a continuous variable versus lymph
node status. Again, neither of these methods revealed a signifi-
cant correlation between Snail expression and lymph node
status in either of the data sets analyzed (Table 2). These find-
ings indicate that Snail expression predicts relapse-free sur-
vival independently of two of the most commonly used prog-
nostic markers for breast cancer relapse.
We next examined the association between Snail expression
and other prognostic indicators, including histological tumor
grade, ER status, and HER2/neu expression. Using analytical
methods similar to those described above, no consistent cor-CANCER CELL : SEPTEMBER 2005was detected (Table 2). Similarly, a correlation between Snail
expression and HER2 expression was observed in only one of
16 such analyses. We were, however, able to detect a statisti-
cally significant negative correlation between Snail expression
and ER expression in two of the four data sets.
We then asked whether Snail expression might correlate with
a specific cellular subtype of breast cancer associated with
poor outcome. Sorlie et al. have previously described array-
based methods for the molecular classification of human
breast cancers into five subtypes: luminal A, luminal B + C,
basal, ERBB2+, and normal breast-like (Sorlie et al., 2001,205
A R T I C L Eshown to be associated with the worst prognosis, whereas the
luminal A subtype has been associated with the best progno-
sis, in both the Sorlie and van’t Veer data sets. Neither contin-
gency table analysis nor continuous variable analysis of Snail
expression differences between these subtypes revealed any
correlation between Snail expression and tumor subtype clas-
sification (Table 2). Similarly, for the Sorlie and Ma data sets,
information was provided regarding whether tumors were of
ductal or lobular origin. Again, Snail expression levels were not
correlated with ductal versus lobular tumor type in either data
set (Table 2). In aggregate, our results indicate that the ability
of Snail expression levels to predict survival is not attributable
to its preferential expression in a previously described aggres-
sive breast cancer subtype.
Finally, although Snail expression did not correlate with most
previously described prognostic markers, we examined whether
adjusting for any of these factors would alter the ability of Snail
expression to predict relapse-free survival. Notably, the associ-
ation between Snail expression and decreased relapse-free
survival remained statistically significant even when adjusted
individually for tumor grade, tumor size, ER status, or HER2
status (Table 3). Therefore, although limited correlations were
observed between Snail expression and either tumor grade or
HER2 status in one data set each, and between Snail and ER
status in two data sets, the correlation between elevated Snail
expression and decreased relapse-free survival is not attribut-
able to any of these associations. Overall, these findings de-
monstrate that Snail expression strongly predicts relapse-free
survival in women with breast cancer and that this association
is largely independent of previously described prognostic
factors.
Discussion
Tumor recurrence is a cardinal manifestation of breast cancer
progression and represents the principal cause of death from
this disease. Preventing relapse by eradicating residual neo-
plastic cells will likely require simultaneous targeting of the
multiple pathways that contribute to tumor survival and pro-
gression. Moreover, with the increasing use of molecularly tar-
geted cancer therapies—many of which are cytostatic—the
identification of molecular pathways that permit tumor cells toTable 3. Proportional hazards analyses of Snail status and selected covariates
van’t Veer Wang
HR 95% CI p value HR 95% CI p value
Snail status 2.09* 1.03–4.24 0.040 N/A N/A N/A
Tumor grade 1.51* 1.51–5.33 0.001 N/A N/A N/A
Snail status 2.12* 1.05–4.29 0.037 N/A N/A N/A
Tumor size 1.70* 1.16–2.49 0.006 N/A N/A N/A
Snail status 2.18* 1.08–4.42 0.030 2.00 0.99–4.02 0.053
ER status 2.15* 1.18–3.94 0.013 1.04 0.65–1.67 0.876
Snail status 2.06* 1.01–4.19 0.046 2.07* 1.07–4.00 0.031
HER2 status 3.68* 1.53–8.86 0.004 1.12 0.66–1.89 0.687
Proportional hazard ratios, confidence intervals, and p values for 5 year relapse-free survival in the van’t Veer et al. (2002) and Wang et al. (2005) data sets based on
Snail expression groups controlled for tumor grade, tumor size, ER status, and HER2 status, and for each of these factors controlled for Snail expression. Asterisks
indicate statistically significant hazard ratios (p < 0.05).206escape blockade of a dominant oncogenic pathway, survive in
a latent state, and eventually reestablish malignant growth has
become even more important. While many animal models de-
veloped over the past two decades have provided insight into
the molecular events leading to tumor development, few have
addressed the molecular and cellular events that lead to recur-
rent disease.
We now present in vivo genetic evidence for a molecular
mechanism that contributes to mammary tumor recurrence.
Our data demonstrate that Snail is spontaneously upregulated
during the process of tumor recurrence in intact animals and
that tumor recurrence is accompanied by EMT, a cellular transi-
tion that has been linked to breast cancer progression and in
which Snail has been implicated. Consistent with a causal role
for Snail in EMT and breast cancer progression, we have fur-
ther shown that Snail is sufficient to induce EMT in primary
tumor cells and to promote mammary tumor recurrence in vivo
and that high levels of Snail expression strongly predict de-
creased relapse-free survival in women with breast cancer.
These observations strongly implicate Snail in the process of
breast cancer recurrence.
Although we identified Snail on the basis of its role in the
recurrence of neu-induced mammary tumors in mice, we have
also shown that the ability of Snail to predict relapse-free sur-
vival in women is not due to its preferential expression within
any currently recognized aggressive subtype of breast cancer.
Moreover, its prognostic significance is independent of the
most robust currently recognized molecular and cellular mark-
ers. If Snail’s role in human tumor recurrence were restricted to
HER2/neu-amplified breast cancers, we would not have ex-
pected to observe a general relationship between Snail expres-
sion and breast cancer recurrence, since HER2/neu-amplified
tumors represent only a small proportion of the cancers in the
data sets examined. Consistent with a more general role for
Snail in human breast cancer recurrence, we have demon-
strated that Snail is not preferentially expressed in HER2/neu-
amplified tumors or in other breast cancer subtypes. Since a
significant association between Snail expression and the likeli-
hood of relapse was observed for both ER-positive and ER-
negative breast cancers, HER2/neu-amplified and unamplified
breast cancers, and breast cancers with and without lymphaticCANCER CELL : SEPTEMBER 2005
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cancer recurrence in a wide variety of clinical contexts.
Importantly, the association that we detected between Snail
expression and disease relapse in humans was observed in
primary tumors, implying that Snail activation within primary
tumors may play a role in promoting tumor recurrence. Consis-
tent with this, we have demonstrated that enforced Snail
upregulation in murine primary tumors is sufficient to promote
tumor recurrence. Moreover, in the small subset of primary
neu-induced tumors that did not regress fully when neu was
downregulated, we identified high levels of Snail expression
comparable to those found in recurrent tumors (Figure 3B).
Nevertheless, it is worth noting that the association between
breast cancer relapse and Snail expression in primary human
tumors is not inconsistent with our observation that spontane-
ous Snail upregulation in this mouse model occurs in recurrent
tumors. First, Snail is expressed at detectable levels in primary
neu-induced tumor cells in mice—albeit at lower levels than in
recurrent tumors. Second, Snail expression levels in recurrent
human breast cancers are at present unknown, since these tu-
mors are generally unavailable for molecular analysis. As such,
based upon our findings in mice, we predict that analysis of
recurrent human breast cancers will reveal elevated levels of
Snail expression compared to primary tumors.
The association between EMT and breast cancer progres-
sion has significant support within the literature, although no
upstream regulator of both processes has previously been
correlated with relapse-free survival. A subset of human breast
cancers and human breast cancer cell lines display features of
EMT (Hajra et al., 2002; Yang et al., 2004); in addition, suppres-
sion of CK8 and expression of vimentin have each been corre-
lated with decreased survival of breast cancer patients (Fuchs
et al., 2002; Niveditha and Bajaj, 2003). Moreover, loss of
E-cadherin expression in breast cancers has been shown to be
positively correlated with advanced histological grade, metas-
tasis, and decreased disease-free as well as overall survival
(Gamallo et al., 1993; Guriec et al., 1996; Heimann et al., 2000).
Given the strong repression of E-cadherin observed in Snail-
expressing tumor samples, the well-described association of
E-cadherin with poor prognosis may in some cases reflect
Snail activity. Indeed, an inverse association between Snail and
E-cadherin expression has been reported in some human
breast cancers (Zhou et al., 2004). Nevertheless, our data do
not address which of Snail’s many functions are most relevant
to recurrence or the maintenance of residual disease.
Snail expression has previously been correlated with histo-
logical grade and lymph node metastasis in a panel of 17 hu-
man breast cancers (Blanco et al., 2002). While we were able
to detect a significant correlation between Snail expression and
histological grade in one breast cancer data set by one method
of analysis, we did not find consistent correlations between
Snail expression and histological grade across most data sets,
nor between Snail expression and lymph node status in any of
the data sets examined. As such, it is possible that in larger,
more diverse tumor sets Snail expression levels may not corre-
late significantly with tumor grade or lymph node status, yet
may remain a significant predictor of relapse-free survival.
Of note, we demonstrated that Snail expression does not
consistently correlate with tumor size, HER2 status, ductal ver-
sus lobular subtype, or luminal versus basal subtype, and that
its prognostic significance is comparable to currently usedCANCER CELL : SEPTEMBER 2005prognostic markers. This suggests that the association be-
tween Snail and relapse-free survival is not simply due to its
selective expression in a presently recognized subset of ag-
gressive breast cancers. Thus, independent of most commonly
used prognostic indicators, high Snail expression identifies a
subset of human breast cancer patients at high risk for recur-
rence. Moreover, the HR associated with increased Snail ex-
pression is comparable to that observed for ER status, which
represents one of the most commonly used clinical prognostic
variables as well as the most commonly used target for breast
cancer prevention and treatment.
Notably, another molecule involved in mesoderm develop-
ment, Twist, has been reported to be a positive regulator of
Snail expression in Drosophila. However, in experiments impli-
cating Twist in tumor metastasis, Yang et al. were unable to
detect induction of Snail in human mammary epithelial cells
induced to undergo EMT by forced Twist expression (Yang et
al., 2004). We were also unable to detect a significant correla-
tion between Twist expression and Snail expression in the Ma,
Sorlie, or Wang human breast cancer data sets (Twist expres-
sion was not available for the van’t Veer data set). This is in
agreement with data suggesting that Snail and Twist function
independently in mice (Carver et al., 2001; Soo et al., 2002).
As such, the observed associations between Twist and metas-
tasis and between Snail and recurrence are likely to represent
independent manifestations of—and mechanisms for—mam-
mary tumor progression.
It is important to note that the findings presented in this
manuscript most directly address the process of local recur-
rence. Isolated local recurrence following breast conservation
surgery with radiation treatment occurs in w10%–20% of
women at 10 years and typically comprises up to one-third of
all recurrences (Doyle et al., 2001; Fisher et al., 1991; Fortin et
al., 1999; Schmoor et al., 2000). As such, local recurrence is in
and of itself a critical problem to understand. However, there
are additional reasons to believe that the findings presented
here may be relevant to distant as well as local recurrence. For
example, a priori considerations alone would suggest that the
processes by which tumor cells—whether local or distant—
survive in a latent state and ultimately reestablish malignant
growth are likely to be related mechanistically. Consistent with
this presumption, multiple studies have demonstrated that lo-
cal recurrence is strongly associated with an increased risk of
both distant relapse (relative risk [RR] = 5.1) and mortality (RR =
3.6) (Doyle et al., 2001; Fisher et al., 1991; Fortin et al., 1999;
Schmoor et al., 2000). Moreover, even the timing of local recur-
rences after surgery is similar to that of distant recurrences
(Demicheli et al., 2004). Together, these observations suggest
that local and distant recurrence may result from similar pro-
cesses. Thus, beyond the recognition that local recurrence is
itself important to understand, the associations between local
and distant recurrence suggest that the mechanisms responsi-
ble for one may be informative for the other. As such, our find-
ings that Snail promotes local recurrence in mice and predicts
local and distant recurrence in humans raise the possibility that
Snail may contribute to both processes.
Similarities between local and distant recurrences notwith-
standing, distinctions between the processes of recurrence
and metastasis must be considered since the mechanisms that
allow latent tumor cells to survive and ultimately reestablish
malignant growth are likely to differ from those that permit207
A R T I C L Eactively growing tumor cells to invade and spread to distant
sites. While metastasis is a sine qua non of distant spread, it
is clearly not required for local recurrence. Moreover, even in
the case of distant recurrence, the mechanisms that permit
metastatic cells to remain in a quiescent state and reemerge at
a later time are not the same as those that permit distant
spread in the first place. As such, while the processes of recur-
rence and metastasis likely share a number of similar features,
distinct mechanisms almost certainly contribute to each pro-
cess. It is therefore essential to distinguish these processes
experimentally to permit elucidation of these separate mecha-
nisms.
Given the enormous number of women at risk for breast can-
cer recurrence, Snail’s ability to predict relapse-free survival in
women, coupled with evidence that Snail promotes the recur-
rence of mammary tumors in mice, suggest that further studies
of this transcriptional repressor may be clinically relevant. Be-
yond the ability to identify women at high risk for relapse, our
findings raise the important possibility that breast cancer recur-
rence might be prevented by therapeutic agents that inhibit
Snail, either by preventing its upregulation or by inhibiting its
function. For example, GSK-3β inhibits Snail transcription and
also promotes its nuclear export and proteasome-dependent
degradation by a phosphorylation-dependent mechanism (Zhou
et al., 2004; Bachelder et al., 2005). Accordingly, inhibition of
GSK-3β activity by the PI3K/AKT, MAPK, and Wnt signaling
pathways promotes Snail stabilization and activation. In addi-
tion, phosphorylation of Snail by Pak1—which is activated by
PI3K via AKT and the small GTPase Rac (Tang et al., 2000)—
enhances Snail’s repressor activity by promoting its nuclear ac-
cumulation (Yang et al., 2005). As such, the development of
cancer therapeutics that target these upstream pathways may
provide a dual mechanism for the inhibition of Snail activity
both by activating GSK-3β and by inhibiting Pak1. Thus, while
it is not possible to confirm a causal role for Snail in human
breast cancer recurrence until drugs are available to inhibit this
pathway, we hypothesize that treatment of patients with phar-
macologic agents that block Snail expression or function may
be effective for preventing breast cancer relapse. Snail may
thereby represent an important new target for a generation of
cancer therapeutics directed against specific molecules in-
volved in breast cancer recurrence.
Experimental procedures
Animals, tissues, immunostaining, and molecular analyses
MMTV-rtTA/TetO-NeuNT mice were engineered, housed, induced with 2
mg/ml doxycycline, monitored for tumor development, and sacrificed as
previously described (Gunther et al., 2002; Moody et al., 2002). Details for
tissue fixation, immunofluorescence, immunohistochemistry, Northern blot-
ting, and microarray analyses are provided in the Supplemental Experimen-
tal Procedures.
Tumor grafting and retroviral transduction
Details for culture of tumor cells harvested from chronically induced MTB/
TAN mice, retroviral transduction, and tumor grafting are provided in the
Supplemental Experimental Procedures.
Human breast cancer data sets
Descriptions of human breast cancer microarray data sets that were interro-
gated and methods used for data analysis, including survival analysis, cal-
culation of HRs, and estimation of the association between Snail expression
and established prognostic factors, are described in detail in the Supple-
mental Experimental Procedures.208Supplemental data
The Supplemental Data include Supplemental Experimental Procedures
and can be found with this article online at http://www.cancercell.org/cgi/
content/full/8/3/197/DC1/.
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